-
Prevalence of Epilepsy in Frontotemporal Dementia and Timing of Dementia Diagnosis JAMA Neurol. (IF 20.4) Pub Date : 2025-06-02
Annemari Kilpeläinen, Mikko Aaltonen, Kalle Aho, Sami Heikkinen, Ave Kivisild, Adolfina Lehtonen, Laura Leppänen, Iina Rinnankoski, Helmi Soppela, Laura Tervonen, Päivi Hartikainen, Annakaisa Haapasalo, Reetta Kälviäinen, Kasper Katisko, Johanna Krüger, Eino SoljeImportancePrevious studies have described a potential association between epilepsy and frontotemporal dementia (FTD), but no systematic data are available.ObjectiveTo determine whether epilepsy is more prevalent in patients with FTD than in healthy controls (HCs) or patients with Alzheimer disease (AD).Design, Setting, and ParticipantsIn this case-control study, we compared the prevalence of epilepsy
-
Antithrombotic Therapy After Burr Hole Evacuation of Chronic Subdural Hematoma JAMA Neurol. (IF 20.4) Pub Date : 2025-06-02
Anders Schack, Frantz Rom Poulsen, Birgit Debrabant, Thorbjørn Søren Rønn Jensen, Rares Miscov, Mette Haldrup, Lejla Islamagič, Ann Kathrine Sindby, Kåre Fugleholm, Bo Bergholt, Carsten Reidies Bjarkam, Anders Rosendal Korshøj, Mads Hjortdal GrønhøjThis study investigates outcomes in patients undergoing surgery for chronic subdural hematoma comparing those receiving vs not receiving antithrombotic therapy.
-
Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia JAMA Neurol. (IF 20.4) Pub Date : 2025-06-02
Jason R. Smith, James Russell Pike, Rebecca F. Gottesman, David S. Knopman, Pamela L. Lutsey, Priya Palta, B. Gwen Windham, Elizabeth Selvin, Moyses Szklo, Karen J. Bandeen-Roche, Josef Coresh, A. Richey Sharrett, Alden L. Gross, Jennifer A. DealImportanceMidlife vascular risk factors are associated with an elevated risk of dementia. However, the total contribution of vascular risk factors in midlife and late life with incident dementia is uncertain.ObjectiveTo quantify the proportion of incident dementia attributable to modifiable vascular risk factors measured in midlife and late life and to examine differences by apolipoprotein ε4 genotype
-
Risk of Parkinson Disease in Individuals With Autism Spectrum Disorder JAMA Neurol. (IF 20.4) Pub Date : 2025-05-27
Weiyao Yin, Abraham Reichenberg, Michal Schnaider Beeri, Stephen Z. Levine, Jonas F. Ludvigsson, Martijn Figee, Sven SandinImportanceRecent research suggests a plausible biological link between autism spectrum disorder (ASD) and Parkinson disease (PD). Nonetheless, large longitudinal studies examining the risk of PD following ASD are lacking.ObjectiveTo examine the association between ASD and future PD risk.Design, Setting, and ParticipantsA nationwide population-based prospective cohort study was performed using data
-
Spontaneous Intracranial Hypotension Due to Cerebrospinal Fluid Rhinorrhea. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-27
Wouter I Schievink,Marcel M Maya,William H Slattery -
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-23
,Ilari Rautalin,Victor Volovici,Benjamin A Stark,Catherine O Johnson,Jaakko Kaprio,Miikka Korja,Rita V Krishnamurthi,Balakrishnan Sukumaran Nair,Annemarei Ranta,Gabriel J E Rinkel,Mervyn D I Vergouwen,Yohannes Habtegiorgis Abate,Hedayat Abbastabar,Foad Abd-Allah,Atef Abdelkader,Parsa Abdi,Arash Abdollahi,Auwal Abdullahi,Olugbenga Olusola Abiodun,Richard Gyan Aboagye,Mohamed Abouzid,Dariush Abtahi,SamirImportance Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective To estimate the worldwide burden of SAH. Design, Setting, and Participants Based on the repeated cross-sectional
-
Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation JAMA Neurol. (IF 20.4) Pub Date : 2025-05-21
John J. McCabe, Yuen Cheung, Marianne Foley, Stephen O. Brennan, Jane Buckley, Pol Camps Renom, Tim Cassidy, Ronan Collins, Eamon Dolan, Gerrit M. Grosse, Joseph Harbison, Kirstyn James, Kayvan Khadjooi, Isuru Induruwa, Mira Katan, Senan Maher, Margaret O’Connor, Martin O’Donnell, Francisco Purroy, Padraig Synott, Peter J. KellyImportanceAtrial fibrillation (AF) is a leading cause of stroke, and oral anticoagulants (OAC) reduce this risk. However, there are limited data on the residual risk of recurrent stroke in patients with AF.ObjectiveTo determine the recurrent stroke risk in patients with AF by performing a systematic review and meta-analysis.Data SourcesEligible studies were identified by searching Ovid MEDLINE and
-
Efficacy and Safety of Eptinezumab in Episodic Cluster Headache JAMA Neurol. (IF 20.4) Pub Date : 2025-05-19
Rigmor H. Jensen, Cristina Tassorelli, Stewart J. Tepper, Andrew Charles, Peter J. Goadsby, Agneta H. Snoer, Bjørn Sperling, Mette Krog Josiassen, Christine Borgen Linander, Anders Ettrup, Neli BonevaImportanceCluster headache, characterized by bouts of excruciating pain attacks, detrimentally affects health and quality of life. Eptinezumab is an anticalcitonin gene-related peptide monoclonal antibody approved for migraine prevention.ObjectiveTo evaluate the efficacy and safety of eptinezumab in the preventive treatment of episodic cluster headache.Design, Setting, and ParticipantsThis double-blind
-
Hemorrhage Into the Canal of Gratiolet JAMA Neurol. (IF 20.4) Pub Date : 2025-05-19
Noriko Nara, Ken JohkuraThis case report describes a unilateral basal ganglia hemorrhage passing through the anterior commissure within the canal of Gratiolet to the contralateral side.
-
Epilepsy at Precision Medicine Crossroads-Disease Modification, Presymptomatic Treatment, and Early Screening. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-12
Alina Ivaniuk,Elia Pestana-Knight,Andreas Brunklaus,Dennis Lal -
Lecanemab Treatment in a Specialty Memory Clinic JAMA Neurol. (IF 20.4) Pub Date : 2025-05-12
Madeline Paczynski, Anna Hofmann, Zachary Posey, Maren Gregersen, Michelle Rudman, Dawn Ellington, Melissa Aldinger, Erik S. Musiek, David M. Holtzman, Randall J. Bateman, Justin M. Long, Nupur Ghoshal, David B. Carr, Alan Dow, Sheyda Namazie-Kummer, Nayid Jana, Chengjie Xiong, John C. Morris, Tammie L. S. Benzinger, Suzanne E. Schindler, B. Joy SniderImportanceTwo monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E)
-
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy JAMA Neurol. (IF 20.4) Pub Date : 2025-05-12
Krista Vandenborne, Glenn A. Walter, Volker Straub, Rebecca J. Willcocks, Sean C. Forbes, Eugenio M. Mercuri, Francesco Muntoni, Kai Ding, Sravya Ennamuri, Carol Reid, Alexander P. Murphy, Marianna Manfrini, Jerry R. Mendell, Jacob S. Elkins, Louise R. Rodino-KlapacImportanceDelandistrogene moxeparvovec is a recombinant adeno-associated virus rhesus isolate serotype 74 vector-based gene transfer therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed pathogenic variant of the DMD gene. In a subset of patients in the EMBARK (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec [SRP-9001]
-
Rizatriptan vs Placebo for Attacks of Vestibular Migraine JAMA Neurol. (IF 20.4) Pub Date : 2025-05-12
Jeffrey P. Staab, Scott D. Z. Eggers, Joanna C. Jen, Allison M. LeMahieu, Jennifer R. Geske, Honghu Liu, Deanna R. Hofschulte, G. Roxana Gonzalez, Brian A. Neff, Neil T. Shepard, Devin L. McCaslin, Robert W. BalohImportanceVestibular migraine has no established treatments.ObjectiveTo test the efficacy of rizatriptan for treating vestibular migraine attacks.Design, Setting, and ParticipantsThis double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers
-
Clinical and Neuropathological Evaluations of the New Brunswick Neurological Syndrome of Unknown Cause JAMA Neurol. (IF 20.4) Pub Date : 2025-05-07
Nathaniel Bendahan, Sylvia Gautreau, Alex Medina Escobar, Gerard H. Jansen, Eslam Abdellah, Sarmad Al-Shamaa, Gabriela S. Gilmour, Lorraine V. Kalia, Sarah C. Lidstone, M. Jason MacDonald, Maria Carmela Tartaglia, Annette Thebeau, Anthony E. LangImportanceIn 2019, an alleged “mystery” neurological illness emerged in New Brunswick, Canada. Despite extensive media attention, no case description has been published to date.ObjectiveTo report on 25 patients with a diagnosis of New Brunswick neurological syndrome of unknown cause (NSUC) who subsequently received a second, independent clinical reassessment or neuropathological examination between
-
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment: Secondary Analysis of the MR CLEAN-LATE Randomized Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-05
Susanne G H Olthuis,Florentina M E Pinckaers,M M Quirien Robbe,Inger R de Ridder,Jan W Hoving,Esmee Venema,Jasper D Daems,F A V Anne Pirson,Julie Staals,Bart J Emmer,Hester F Lingsma,Stefan D Roosendaal,Anouk van der Hoorn,Miou S Koopman,Alida A Postma,Diederik W J Dippel,Charles B Majoie,Robert J van Oostenbrugge,Wim H van Zwam,Importance MR CLEAN-LATE (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands for Late Arrivals) showed efficacy of endovascular treatment (EVT) in the late window (6-24 hours after stroke symptom onset or time last seen well) among patients with ischemic stroke selected based on collateral flow. Therefore, the future role of computed tomography
-
General AI May Revolutionize Neurology—Or It Might Be Bad JAMA Neurol. (IF 20.4) Pub Date : 2025-05-05
M. Brandon Westover, Alek M. WestoverThis Viewpoint urges neurology stakeholders to consider the potential dangers of the proliferation of artificial intelligence (AI) in neurology, as well as across the wider health care field.
-
Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder JAMA Neurol. (IF 20.4) Pub Date : 2025-05-05
Richard B. Lipton, Verena Ramirez Campos, Zipi Roth-Ben Arie, Maja Galic, Dimos Mitsikostas, Cristina Tassorelli, Lex Denysenko, Joshua M. CohenImportanceMigraine and major depressive disorder are frequently comorbid; however, evidence evaluating the efficacy of preventive migraine therapy in patients with both diseases is limited.ObjectiveTo evaluate the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder.Design, Setting, and ParticipantsThe UNITE study was a double-blind, placebo-controlled
-
Functional Seizures-A Critical Comorbidity Overlooked in Epilepsy Research. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-28
Mahinda Yogarajah,Barbara Dworetzky,Ley Sander -
Functional Seizures-A Critical Comorbidity Overlooked in Epilepsy Research-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-28
Churl-Su Kwon,Nathalie Jetté,Charles R Newton -
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia JAMA Neurol. (IF 20.4) Pub Date : 2025-04-28
Tobias Borgh Skillbäck, Linus Jönsson, Ingmar Skoog, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg, Silke KernImportanceThe defining pathological features of Alzheimer disease (AD) may also be contributing factors in other dementias.ObjectiveTo examine the prevalence of β-amyloid (Aβ) and tau pathophysiological changes as indicated by cerebrospinal fluid biomarkers, as well as their association with clinical disease progression, across a broad range of dementias.Design, Setting, and ParticipantsIn this cross-sectional
-
Do Neurologists Need a Goldwater Rule? JAMA Neurol. (IF 20.4) Pub Date : 2025-04-28
Farrah J. MateenThis Viewpoint examines whether neurologists, like psychiatrists, should adopt a Goldwater Rule, an ethical principle prohibiting comments about and diagnoses of public persons they have not personally examined.
-
Aspirin Continuation or Discontinuation in Surgically Treated Chronic Subdural Hematoma: A Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-27
Maria Kamenova,Lea Pacan,Christian Mueller,Michael Coslovsky,Katharina Lutz,Serge Marbacher,Manuel Moser,Anne-Katrin Hickmann,Christian Zweifel,Raphael Guzman,Luigi Mariani,Jehuda Soleman,Importance Discontinuation of low-dose acetylsalicylic acid (ASA) during the perioperative phase of treatment for chronic subdural hematoma (cSDH) may reduce recurrence rates but may also increase the risk of cardiovascular or thromboembolic events. However, the efficacy and safety of discontinuing ASA in this patient population remain unclear. Objective To assess the risk of recurrence of cSDH and
-
"I'm as Mad as Hell and I'm Not Going to Take This Anymore!" JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
David N Korones -
Do the Benefits of Blood Pressure Control in ICH Outweigh the Risks? JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
Jessica Magid-Bernstein,Santosh B Murthy -
IWG and AA Criteria-Where the Differences Matter. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
Andrew M Kiselica,Leslie S Gaynor,Kelly J Atkins -
IWG and AA Criteria-Where the Differences Matter-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
Bruno Dubois,Nicolas Villain,Howard H Feldman -
IWG and AA Criteria-Where the Differences Matter. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
Clifford R Jack,Maria C Carrillo,Reisa A Sperling -
Acute Blood Pressure Lowering and Risk of Ischemic Lesions on MRI After Intracerebral Hemorrhage JAMA Neurol. (IF 20.4) Pub Date : 2025-04-21
Ken S. Butcher, Brian Buck, Dar Dowlatshahi, Laura C. Gioia, Mahesh Kate, Ana C. Klahr, Ashwin Sivasubramaniam, Ashfaq Shuaib, Alan Wilman, Vijay K. Sharma, Georgios Tsivgoulis, Christos Krogias, Ashkan ShoamaneshImportanceDiffusion-weighted imaging (DWI) lesions have been demonstrated in patients with subacute intracerebral hemorrhage (ICH), suggesting ischemic injury, which may be related to blood pressure (BP) reduction.ObjectiveTo test the hypothesis that acute intensive BP lowering is associated with DWI lesions after ICH.Design, Setting, and ParticipantsThe Intracerebral Hemorrhage Acutely Decreasing
-
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,OliverImportance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis
-
The Risk of Alzheimer Disease in APOE4 Homozygotes. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Eric M Reiman,Valentina Ghisays,Jessica B Langbaum -
Risk of Poststroke Epilepsy Among Young Adults With Ischemic Stroke or Intracerebral Hemorrhage JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Esmée Verburgt, Lina Fellah, Merel S. Ekker, Mijntje M. I. Schellekens, Esther M. Boot, Maikel H. M. Immens, Mayte E. van Alebeek, Paul J. A. M. Brouwers, Renate M. Arntz, Gert W. van Dijk, Rob A. R. Gons, Inge W. M. van Uden, Tom den Heijer, Julia H. van Tuijl, Karlijn F. de Laat, Anouk G.W. van Norden, Sarah E. Vermeer, Marian S. G. van Zagten, Robert J. van Oostenbrugge, Marieke J. H. Wermer, PaulImportancePoststroke epilepsy (PSE) is a major complication among young adults and is associated with problems with functional recovery and daily life. Although scores have been developed to predict risk of PSE, they have not been validated among patients with stroke at a young age.ObjectivesTo investigate both the risk of and risk factors for PSE at a young age and validate current PSE risk scores
-
Tongue Myokymia in IgLON5-IgG Autoimmunity JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Shemonti Hasan, Divyanshu Dubey, Allen AksamitThis case report discusses a man who tested positive for IgLON5-IgG antibody after intermittent episodes of paresthetic feeling involving the throat and jaw, associated with subtle dysarthria and dysphagia, and upper-extremity paresthesia with piloerection of the forearms.
-
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Ifrah Zawar, Mark Quigg, Emily L. Johnson, Soutik Ghosal, Carol Manning, Jaideep KapurImportanceThe risk of developing epilepsy substantially increases after the age of 60 years (late-onset epilepsy [LOE]), particularly in people with cognitive decline ([PWCD] ie, dementia and/or mild cognitive impairment). Epilepsy is associated with worse cognitive and mortality outcomes in PWCD. Identifying PWCD at risk for developing LOE can facilitate early screening and treatment of epilepsy.ObjectiveTo
-
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis JAMA Neurol. (IF 20.4) Pub Date : 2025-04-14
Daniel T. Myran, Michael Pugliese, Lyndsay D. Harrison, Nathan M. Stall, Colleen WebberImportanceCannabis use is associated with short-term memory impairment and long-term changes in brain structure; however, little is known about whether disordered cannabis use is associated with an increased risk of a dementia diagnosis.ObjectiveTo investigate the association between emergency department visits or hospitalizations (acute care encounters) due to cannabis and future dementia diagnosis
-
Possible Explanations for Hearing Loss in Parkinson Disease-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Lee E Neilson,Kelly M Reavis,Gregory D Scott -
Possible Explanations for Hearing Loss in Parkinson Disease. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Abdullah Yasir Yilmaz,Joseph Jankovic -
GLP-1 Receptor Agonists-From Breakthroughs in Cardiometabolic Treatment to Emerging Neuroprotective Potential. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Diana Thiara -
Apraxia of Eyelid Opening in Myasthenia Gravis JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
Ryan Naum, Jonathan MorenaThis case report describes a 61-year-old man with myasthenia gravis initially diagnosed with blepharospasm who was later found to have the nonparalytic disorder apraxia of eyelid opening.
-
The Regulatory Landscape for Clinical Metagenomic Testing JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
Charles Y. Chiu, F. Xavier López-Labrador, Michael R. Wilson, Jutte J. C. de VriesThis Viewpoint discusses regulatory shifts and their effects on access to innovative diagnostic tests and provides ways to address regulatory barriers for clinical metagenomic testing.
-
Cardioprotective Glucose-Lowering Agents and Dementia Risk JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
Allie Seminer, Alfredi Mulihano, Clare O’Brien, Finn Krewer, Maria Costello, Conor Judge, Martin O’Donnell, Catriona ReddinImportanceAlthough diabetes is a risk factor for dementia, the effect of glucose-lowering therapy for prevention of incident dementia is uncertain.ObjectiveTo determine whether cardioprotective glucose-lowering therapy (sodium-glucose cotransporter-2 inhibitors [SGLT2is], glucagon-like peptide-1 receptor agonists [GLP-1RAs], metformin, and pioglitazone), compared with controls, was associated with
-
Use of a Robot-Assisted Thrombectomy System in Acute Ischemic Stroke JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
Ming Yang, Haoquan Sun, Lei Li, Qi Wu, Xingkai Yang, Shen Qu, Feng GaoThis observational study examines the feasibility and safety of a new preloaded robot-assisted thrombectomy system specifically designed for mechanical thrombectomy.
-
Mind the Itch JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
David MatuskeyThis essay details the author’s personal experience with poison ivy itch and the synchronicity of a similar realization for a patient at his former facility.
-
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias JAMA Neurol. (IF 20.4) Pub Date : 2025-04-07
Huilin Tang, William T. Donahoo, Steven T. DeKosky, Yao An Lee, Pareeta Kotecha, Mikael Svensson, Jiang Bian, Jingchuan GuoImportanceThe association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed.ObjectiveTo assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D).Design, Setting, and ParticipantsThis target trial emulation study
-
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Vincent Bouteloup,Nicolas Villain,Jean Sebastien Vidal,Fernando Gonzalez-Ortiz,Idil Yuksekel,Cristiano Santos,Susanna Schraen-Maschken,Isabelle Pellegrin,Sylvain Lehmann,Kaj Blennow,Geneviève Chêne,Olivier Hanon,Carole Dufouil,Vincent Planche,Importance Blood phosphorylated tau 217 (p-tau217) showed good performance in predicting brain amyloidosis. However, the importance of detailed cognitive phenotyping in patients without dementia when interpreting p-tau217 results remains unclear. Objective To assess whether accuracy, negative predictive value (NPV), and positive predictive value (PPV) in predicting brain amyloidosis using p-tau217
-
-
Errors in Abstract, Methods, Results, Figure 2, and Conflicts of Interest. JAMA Neurol. (IF 20.4) Pub Date : 2025-04-01
-
Immortal Time Bias and Nonlinear Stroke Recurrence Risk-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Lucas V A Boersma,David J Werring,David J Seiffge -
Immortal Time Bias and Nonlinear Stroke Recurrence Risk. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Raed A Joundi,Shrikant I Bangdiwala,Mukul Sharma -
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis JAMA Neurol. (IF 20.4) Pub Date : 2025-03-31
Liza M. Y. Gelissen, Martijn T. Wijburg, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Theo Rispens, Mariet C. W. Feltkamp, Zoé L. E. van Kempen, Joep KillesteinThis cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.
-
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy JAMA Neurol. (IF 20.4) Pub Date : 2025-03-31
Asbjorg Osk Snorradottir, Alvaro Gutierrez-Uzquiza, Paloma Bragado, Michael E. March, Charlly Kao, Enrico Bernardo Arkink, Solveig Jonsdottir, Arna Sigurdardottir, Helgi J. Isaksson, Hekla Liv Mariasdóttir, Olga Yr Bjorgvinsdottir, Natalia M. Kowal, Hugrun L. Heimisdottir, Astros Sverrisdottir, Astridur Palsdottir, Hans Tomas Bjornsson, Hakon HakonarsonImportanceHereditary cystatin C amyloid angiopathy (HCCAA) is a lethal, dominantly inherited disease primarily affecting Icelandic young adults that leads to severe cerebral amyloid angiopathy, with no effective therapy.ObjectiveTo investigate safety, tolerance, and therapeutic potential of N-acetylcysteine (NAC) in lowering disease-associated biomarkers in sequence variation carriers.Design, Setting
-
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation JAMA Neurol. (IF 20.4) Pub Date : 2025-03-31
Steven J. Warach, Lisa A. Davis, Patrick Lawrence, Byron Gajewski, Jo Wick, Fred Shi, Ty T. Shang, DaiWai M. Olson, Sidarrth Prasad, Lee Birnbaum, Jody M. Richardson, Sean I. Savitz, Mark P. Goldberg, Salvador Cruz-Flores, Israel Alba, Jane Anderson, Barbara Kimmel, Chethan P. Venkatasubba Rao, Ben King, Adrienne N. Dula, Truman J. MillingImportanceClinical practice guidelines recommend initiation of anticoagulation within 2 weeks after stroke with atrial fibrillation. It is unknown whether there is an optimal starting day within the 14-day period that balances the risks of recurrent embolic events against serious hemorrhagic events.ObjectiveTo determine if there is an optimal delay time to initiate treatment with a direct oral anticoagulant
-
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Jeremy M Shefner,Merit E Cudkowicz,Angela Genge,Orla Hardiman,Ammar Al-Chalabi,Jinsy A Andrews,Adriano Chio,Philippe Corcia,Philippe Couratier,Mamede de Carvalho,Terry Heiman-Patterson,Robert D Henderson,Caroline Ingre,Wendy Johnston,Albert Ludolph,Nicholas J Maragakis,Timothy M Miller,Jesus S Mora,Susanne Petri,Zachary Simmons,Leonard H van den Berg,Lorne Zinman,Stuart Kupfer,Fady I Malik,Lisa MengImportance Treatment options for amyotrophic lateral sclerosis (ALS) remain suboptimal. Results from a phase 2 study of reldesemtiv in ALS suggested that it may slow disease progression. Objective To assess the effect of reldesemtiv vs placebo on functional outcomes in ALS. Design, Setting, and Participants A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral
-
Sonographic Demonstration of Myopathy in Mycosis Fungoides JAMA Neurol. (IF 20.4) Pub Date : 2025-03-24
David Kravitz, Erel Joffe, Alon AbrahamThis case report describes a diagnosis of muscle infiltration of mycosis fungoides in a female aged 36 years with initial disease manifesting as pigmented skin patches.
-
The Neurologist’s Imperative in Brain Death JAMA Neurol. (IF 20.4) Pub Date : 2025-03-24
David M. Greer, Ariane Lewis, Matthew P. KirschenThis Viewpoint discusses the importance of the diagnosis of brain death/death by neurologic criteria and provides context and history of the diagnosis.
-
Venture Capital Investment in Neurology Companies. JAMA Neurol. (IF 20.4) Pub Date : 2025-05-01
Ravi Dhawan,Alex B Boyle,Hithardhi Duggireddy,Margherita Rampichini,Denys Shay -
Belly Dancer’s Dyskinesia Following Acute Corpus Callosum Infarction JAMA Neurol. (IF 20.4) Pub Date : 2025-03-17
Juntao Yin, Yuqing Wei, Lixin GuoThis case report describes a patient with spontaneous, arrhythmic, spasmodic contractions of the abdominal muscles whose imaging confirmed involvement of the genu, body, and splenium of the corpus callosum.
-
Health Information Seeking-CTE Perception and Suicide. JAMA Neurol. (IF 20.4) Pub Date : 2025-03-10
Ririka Tanikawa,Tatsuya Fujikawa -
Health Information Seeking-CTE Perception and Suicide-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-03-10
Rachel Grashow,Douglas P Terry,Aaron L Baggish -
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2025-03-10
Jennifer A. Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D. Evans, Ming Lu, JonDavid Sparks, Scott Andersen, Steve Lauzon, Emel Serap Monkul Nery, Chakib Battioui, Staci E. Engle, Alessandro Biffi, Diana Svaldi, Stephen Salloway, Steven M. Greenberg, Reisa A. Sperling, Mark Mintun, Dawn A. Brooks, John R. SimsImportanceAmyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.ObjectiveTo characterize ARIA in participants treated with donanemab.Design, Setting, and ParticipantsThese prespecified and post hoc exploratory
-
Cerebral White Matter Abnormality Features of Encephalitis Caused by Angiostrongylus cantonensis JAMA Neurol. (IF 20.4) Pub Date : 2025-03-10
He Li, Yang Cheng, Wei TangThis case report describes cerebral white matter abnormalities from encephalitis caused by Angiostrongylus cantonensis in a 60-year-old woman.